Description: Thousands of species of bacteria and other microorganisms reside in the human digestive system. Several disease including cancer and autoimmune disorders such as multiple sclerosis, are thought to be influenced by processes that occur within the gut microbiome. The ability to develop microbiome formulations that can target specific gastrointestinal areas could hold the key to combating these diseases. Areas of therapeutic focus include C. Difficile Infections, unspecified Gastrointestinal disorders and inflammatory bowel syndrome. Active clinical trials comprise probiotics, prebiotics, synbiotics, bacterial transplantation, antimicrobials, microbiome-modulating agents, monoclonal antibodies and others. Evonik has developed a portfolio of functional excipients and delivery technologies that are designed to help create formulations to optimize microbe performance after oral application. Evonik will present formulations and application examples as to how these oral solutions can improve microbe survival, controlled transit, residence time and site targeting, as well as to reduce pill burden for improved patient adherence.
upon completion, participant will be able to demonstrate knowledge for safely and successfully deliver microbiome based therapeutic agents with oral targeted delivery with full potential.
upon completion, participant will be able to identify specific functional excipients and technology required for the specific type of microbiome targeting specific area in GIT.
upon completion, participant will be able to provide comprehensive approach in microbiome oral formulation development for effective treatment of specific diseased conditions.